Back to top
more

Sage Therapeutics (SAGE)

(Delayed Data from NSDQ)

$6.05 USD

6.05
1,060,671

-0.03 (-0.49%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $6.06 +0.01 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake

by Zacks Equity Research

Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.

What's in Store for Biogen (BIIB) This Earnings Season?

by Zacks Equity Research

Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.

Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success

by Zacks Equity Research

Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.

Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal

by Zacks Equity Research

Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report?

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae. Stock rise.

Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls

by Zacks Equity Research

Biogen (BIIB) misses fourth-quarter estimates for earnings and sales. Sales of Tecfidera, Tysabri & Spinraza decline.

Can Biogen (BIIB) Keep the Beat Streak Alive in Q4 Earnings?

by Zacks Equity Research

Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.

Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline

by Zacks Equity Research

Perspective Therapeutics (CATX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Sage Therapeutics, Inc. (SAGE) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Sage Therapeutics, Inc. (SAGE) Up 12.7% Since Last Earnings Report?

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5%

by Zacks Equity Research

Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course.

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -6.44% and 69.89%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More

by Zacks Equity Research

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.

VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sundeep Ganoria headshot

Sage's (SAGE) Huntington's Disease Drug Gets FDA's Orphan Tag

by Sundeep Ganoria

The FDA grants orphan drug designation to Sage Therapeutics' (SAGE) SAGE-718 for treating Huntington's disease. The designation will help incentivize the development of the candidate.

Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why

by Zacks Equity Research

While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like Leqembi in Alzheimer's disease, Qalsody in amyotrophic lateral sclerosis and zuranolone in depression, can help revive growth.

Sage Therapeutics (SAGE) Plunges 46% in a Month: Here's Why

by Zacks Equity Research

The plunge in Sage's (SAGE) shares comes after the FDA declined to approve Zurzuvae in major depressive disorder indication, citing management to conduct more clinical studies.

Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News

by Zacks Equity Research

Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.

Company News for Aug 8, 2023

by Zacks Equity Research

Companies in The News Are: KKR,SAGE,VTRS,FRPT

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -5.93% and 15.19%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far

by Zacks Equity Research

Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.60% and 35.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?